Ongoing monitoring Ability to pause or adjust anytime Support throughout the process Semaglutide A once-weekly GLP-1 receptor agonist injection used to treat type 2 diabetes and chronic weight management in adults who are overweight or obese
doi: 10.1016/j.radcr.2022.02.035
da Silva LE, de Oliveira MP, da Silva MR, Abel Jda, Tartari S, de Costa G et al
When tested in clinical trials, this drug was found to be highly effective
The insurer said in a statement to Fierce Healthcare that it will no longer cover GLP-1s in its large group fully insured plans as of Jan
A limitation of the multiple-dose trial was the low number of subjects with T2D, implying that, in particular, the pharmacodynamic results from this trial should be interpreted carefully